Skip to main content
Premium Trial:

Request an Annual Quote

Intermountain, Decode Genetics to Sequence 500K Genomes for Research

NEW YORK (GenomeWeb) – Intermountain Healthcare has inked a collaboration with Amgen subsidiary Decode Genetics to whole-genome sequence 500,000 patients and study the underlying causes disease.

Within the population health study, called HerediGene, Intermountain and Decode will enroll and analyze the genomes of half-a-million individuals who receive care at the non-profit healthcare system serving Utah and Idaho. Consenting participants will be sequenced for free and their deidentified data will be used for research to improve understanding of the causes of disease and develop treatments. Participants will also have the chance to learn whether they harbor clinically actionable variants associated with diseases.

"While the 500,000 samples will be collected primarily from patients in Utah, the research is expected to have a global impact as medications, treatments, and healthcare innovations that can benefit patients universally are developed from the findings," Lincoln Nadauld, Intermountain’s chief of precision health, said in a statement.

Decode CEO Kári Stefánsson added in a statement that the collaboration will be important to the company's ongoing work to identify and validate new disease targets. In 2012, biopharmaceutical firm Amgen acquired Icelandic firm Decode for $415 million in order to use its cache of genomic and medical data to inform and expedite drug development efforts.  

"These potential discoveries [from the Intermountain collaboration] will allow Decode and Amgen to rapidly develop new medicines that reach the right disease targets," Stefánsson stated.

Read the premium article for more details on this collaboration.

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.